Neogenomics

Neogenomics focuses on oncology testing with a portfolio of over 500 diagnostic tests including broad-panel DNA and RNA-based next-generation sequencing. In addition it provides pharma services such as support for oncology-focused research and clinical trials in biomarker discovery, developing a companion diagnostic, and custom assay design and development. The company also leverages data to facilitate the discovery and development of new therapeutic options, support clinical trial matching, assess therapy outcomes, and deliver personalized care.

For its diagnostic services the company uses approaches such as anatomic pathology, cytogenetics, fluorescence in situ, flow cytometry and next generation sequencing.

The company’s sponsored testing programs as of October 2023 included FOLR1 cancer testing program, KRAS single gene test program and PIK3CA Mutation CDx.

In October 2023 NeoGenomics launched two new tests: Neo Comprehensive - Heme Cancers and Early-stage NSCLC Panel.

Neo Comprehensive - Heme Cancers is a large and comprehensive next-generation sequencing panel with broad coverage of genes (433 genes) associated with blood cancers. The company claims that this test provides key diagnostic information, such as critical molecular determinations affecting therapeutic approaches, aids in risk stratification, predicts prognosis, and can be used in clinical research. The early-stage NSCLC Panel is a therapy selection panel providing a comprehensive overview of biomarkers for detecting early-stage lung cancer. This panel reportedly offers clinicians an evidence-based set of actionable markers to support the management of patients with early-stage lung cancer. 

Key customers and partnerships

The company partnered with bioinformatics platform Massive Bio in March 2023 to accelerate the development of cancer treatments. Under this, NeoGenomics intends to use real-time identification to identify patients that qualify for clinical trials based on their biomarker status. Massive Bio is expected to support NeoGenomics with obtaining patient consent and accelerating the process of further screening and possible enrollment. Reportedly, through this collaboration, patients who meet the criteria for clinical trials can be identified, allowing patients and healthcare providers to make informed decisions about their potential treatment options.

Funding and financials

In May 2021, the company raised USD 200 million in a post-IPO equity round.